// App-Quantinova.ai

OC 40.4 : Safety and Efficacy of Emicizumab in People with Hemophilia A Enrolled in the Hemophilia Natural History Study (ATHN 7)

Researchers

Presenter

  • T. Buckner

Principal Investigators

  • S. L. Carpenter

  • C. Kempton

  • L. Lee

  • L. Malec

  • J. Staber

  • M. Wang

  • M. Recht

Medical Centers

  • Hemophilia and Thrombosis Center, University of Colorado School of Medicine, Aurora, CO, United States

  • Kansas City Regional Hemophilia Center, Kansas City, Montana, United States

  • Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Atlanta, United States

  • Second Genome, Inc., South San Francisco, California, United States

  • Blood Research Institute, Milwaukee, Wisconsin, United States

  • Wake Forest University Medical Center, Winston Salem, North Carolina, United States

  • Iowa Regional Hemophilia and Thrombosis Center/University of Iowa, Iowa City, United States

  • University of Colorado Hemophilia & Thrombosis Center, Aurora, United States

  • American Thrombosis Hemostasis Network, Rochester, United States

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

Disease

  • Hemophilia

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • FVIII

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • NCT03619863

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved